A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

BACKGROUND: Dalpiciclib (SHR6390) is a novel inhibitor of cyclin-dependent kinase 4/6 which demonstrated promising anti-tumor potency in preclinical models. This first-in-human study was conducted to evaluate the tolerability, pharmacokinetics, safety, and preliminary antitumor activity of dalpicicl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pin, Xu, Binghe, Gui, Lin, Wang, Wenna, Xiu, Meng, Zhang, Xiao, Sun, Guilan, Zhu, Xiaoyu, Zou, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042970/
https://www.ncbi.nlm.nih.gov/pubmed/33845905
http://dx.doi.org/10.1186/s40364-021-00271-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042970/
https://www.ncbi.nlm.nih.gov/pubmed/33845905
http://dx.doi.org/10.1186/s40364-021-00271-2

Ejemplares similares